Sébastien Henry - Concepedia

Concepedia

Author

Sébastien Henry

Georgia Institute of Technology ORCID

Also Known As

Henry, Sébastien, S Henry, S O Henry, S. Henry, Sebastien Henry, Sébastien Henry

21

Publications

2.4K

Citations

12

H-Index

22

Concepts

All Affiliations

Georgia Institute of Technology Micron Biomedical (United States)Centers for Disease Control and Prevention MRC Unit the Gambia HOPE Clinic

SH

About

Sébastien Henry is an author at Georgia Institute of Technology specializing in medicine, dermatology, and biofabrication.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	874
2	Engineering	1	1	115
3	Biomedical Engineering	1	1	115
4	Immunology	1	1	411
5	Cancer Therapeutics	1	1	125

Sébastien Henry

×

10

Publications

2.4K

Citations

10

H-Index

	Year	Citations
Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery Sébastien Henry, Devin V. McAllister, Mark G. Allen, Journal of Pharmaceutical Sciences	1998	1.3K
The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial Nadine Rouphael, Michele Paine, Regina Mosley, The Lancet VaccinationVaccine SafetyCross-protectionVaccinologyMicroneedle Patch	2017	411
Tolerability, usability and acceptability of dissolving microneedle patch administration in human subjects Jaya Arya, Sébastien Henry, Haripriya Kalluri, Biomaterials MedicineHuman SubjectsDermatologyMicroneedle Patch Administration	2017	223
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial Xavier Pivot, Gilles Romieu, Marc Debled, The Lancet Breast OncologyOncologyEarly Breast CancerRandomised TrialBreast Cancer	2019	125
Micromachined needles for the transdermal delivery of drugs Sébastien Henry, Devin V. McAllister, Mark G. Allen, Tissue EngineeringNanomedicineTransdermal DeliveryEngineeringMicrofabrication	2002	115
A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial Ikechukwu Adigweme, Mohammed Nakodi Yisa, Michael Ooko, The Lancet	2024	67
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine Sung-Sil Moon, Marly Richter-Roche, Theresa K. Resch, npj Vaccines	2022	35
Immunologic mechanisms of seasonal influenza vaccination administered by microneedle patch from a randomized phase I trial Nadine Rouphael, Lilin Lai, Sonia Tandon, npj Vaccines	2021	30
Absolute Triangulation Algorithms for Space Exploration Sébastien Henry, John A. Christian Journal of Guidance Control and Dynamics	2022	26
Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial] Ikechukwu Adigweme, Edem Akpalu, Mohammed Nakodi Yisa, Trials	2022	21

Page 1